Ignite Creation Date:
2024-05-06 @ 10:42 AM
Last Modification Date:
2024-10-26 @ 12:33 PM
Study NCT ID:
NCT03321695
Status:
COMPLETED
Last Update Posted:
2023-03-13
First Post:
2017-10-20
Brief Title:
A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Observational Study of the Safety of Atezolizumab in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
Status:
COMPLETED
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study of the safety and effectiveness of atezolizumab in participants with metastatic non-small cell lung cancer NSCLC who have disease progression during or following platinum-containing chemotherapy Participants also will have progressed on an appropriate approved targeted therapy if their tumor has epidermal growth factor receptor EGFR or anaplastic lymphoma kinase ALK gene abnormalities treated in common clinical practice settings in Argentina
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None